The Longevity Industry Isn't Science Yet

Longevity science is a legitimate research field. The mechanisms of cellular ageing — telomere shortening, mitochondrial dysfunction, senescent cell accumulation, epigenetic drift — are well-characterised at the molecular level. Mouse lifespans have been extended repeatedly in controlled laboratory conditions. The gap between mouse models and human clinical outcomes is vast, routinely underestimated, and financially inconvenient for a growing industry.

What We Actually Know

Caloric restriction extends lifespan in yeast, worms, flies, and mice. Results in primates are mixed. The one human study with reasonable methodology — the CALERIE trial — showed modest metabolic improvements, not lifespan extension. Metformin, the diabetes drug that is also taken prophylactically by thousands of longevity enthusiasts, has a large observational evidence base showing association with reduced all-cause mortality in diabetic populations. Whether it extends lifespan in non-diabetic people is untested in any randomised trial.

Rapamycin — an immunosuppressant that inhibits mTOR — reliably extends lifespan in mice, even when administered late in life. Human trials are limited. The drug has meaningful side effects including increased infection susceptibility. The longevity community has largely decided these risks are acceptable; the clinical evidence base for that decision does not yet exist.

The Capital Problem

Altos Labs has raised $3 billion. Calico (Google) has spent over $2 billion over a decade with no published clinical results. Unity Biotechnology, which targeted senescent cells, failed its phase 2 trials and pivoted. The capital entering this field is extraordinary by any historical standard for a research area without a single approved therapeutic.

This creates a specific distortion: companies need to raise money on the basis of animal data and mechanistic plausibility. The incentive is to maximise the salience of positive signals and minimise the weight given to translational failures. The longevity-focused press has largely adopted the industry's framing, treating mouse lifespan extension as if it directly implies human outcomes.

The Bryan Johnson Problem

Johnson's "Blueprint" project is useful for understanding the sociology of longevity optimism rather than its science. He publishes extensive biomarkers. His medical team is real. His compliance is extraordinary. The problem is that he has no control group and is simultaneously testing dozens of interventions, making it impossible to attribute any outcome to any cause. This is not a clinical trial. It is a documented experiment on a sample of one, filtered through the perspective of someone who has every incentive to interpret the results positively.

The blood plasma transfusions popularised by Ambrosia (now shut down by the FDA) and discussed in various tech circles have no credible human clinical evidence. The FDA has issued warnings. The mechanism that works in parabiosis mouse experiments has not translated to human benefit in any controlled study.

The Reasonable View

The research is worth funding. The mechanisms are real. Some intervention will eventually reach clinical validation. The reasonable estimate from careful geroscience researchers like David Sinclair (Harvard) and Aubrey de Grey (SENS Research Foundation) has consistently been that meaningful human lifespan extension is decades away, not available now. The investment community and self-experimenting tech founders are operating on a timeline that the underlying science does not support. That gap — between what is being sold and what is known — is where the health risk lies.